ASH 2018 | The future of AML therapy
Andreas Burchert, MD, of the University of Marburg, Marburg, Germany, speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., reveals that chemotherapy remains the standard of care for acute myeloid leukemia (AML), before introducing the transition from chemotherapy to molecular target therapies as the future of AML treatment. Prof. Burchert also talks about SORMAIN trial, utilizing molecular therapy to improve the outlook for patients with FLT3-ITD-positive AML.
